FortuneRock

About FortuneRock

FortuneRock (China) Co., Ltd. is a clinical-stage biopharmaceutical company headquartered in Beijing, China, established in 2010. The company, chaired by Prof. Zailin Yu, specializes in the research, development, and commercialization of long-acting and novel recombinant protein drugs. Its core business revolves around creating treatments for life-threatening and debilitating conditions, including various cancers and hepatitis B and C.

The company's primary technology is its proprietary Long Acting Recombinant Protein Drug Platform, which utilizes fusion technology with human serum albumin to extend the effective life of therapeutic proteins. This approach is designed to reduce the frequency of injections for patients, a significant benefit over existing treatments that may require daily or weekly doses. For instance, one of its lead candidates, a long-acting drug for chemically induced neutropenia, aims to change the injection schedule from daily to once every two weeks. FortuneRock also leverages a High Efficacy Yeast Expression System Platform, enabling the large-scale production of high-quality recombinant protein products.

FortuneRock's business model encompasses the entire drug development lifecycle, from preclinical studies to clinical trials and eventual commercialization. It also engages in contract research (CRO) and sales (CSO) activities, providing outsourcing services for recombinant protein production to partners. The company has actively pursued intellectual property protection, with 26 patents filed or granted in the USA and China. A notable milestone occurred in June 2013, when FortuneRock sold non-exclusive US rights for a patented technology to a major global pharmaceutical company. The company went public on China's National Equities Exchange and Quotations (NEEQ) on July 30, 2015, under the ticker NEEQ:833178. Before its acquisition on December 28, 2022, FortuneRock had raised significant venture capital, with investors including HuaAn Future Asset, JT Asset Management, and Jinhua Pharmaceutical.